$EW · Edwards Lifesciences Corp
On November 19, 2026, Edwards Lifesciences entered into an Amended and Restated Five Year Credit Agreement, replacing its July 15, 2022 facility. The new agreement provides a five-year $750 million multi-currency unsecured revolving credit facility, expandable by up to $375 million, maturing November 19, 2031. Borrowings bear interest at SOFR or base rate plus a margin tied to leverage ratio or debt ratings. No amounts have been borrowed as of the filing date.
- New facility is a $750M multi-currency unsecured revolver.
- Maturity extended to November 19, 2031.
- Facility can be increased by up to $375M with lender agreement.
- Interest margin is based on leverage ratio or debt ratings.
- No amounts borrowed as of the filing date.
Markets closed — no regular-session reaction yet; extended-hours move not captured here.
Routine balance-sheet refresh that extends maturity and improves terms, with no immediate borrowing.
_Not applicable._
Customary covenants include a maximum leverage ratio; an event of default could accelerate all obligations.